Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

Neurology

Volumn 56, Issue 7, 2001, Pages 843-848

  Miller, R G ^a   Moore II, D H ^a,o   Gelinas, D F ^a   Dronsky, V ^a   Mendoza, M ^a   Barohn, R J ^b   Bryan, W ^b   Ravits, J ^c   Yuen, E ^c   Neville, H ^d,e   Ringel, S ^d   Bromberg, M ^f   Petajan, J ^f   Amato, A A ^g   Jackson, C ^g   Johnson, W ^h   Mandler, R ⁱ   Bosch, P ^j   Smith, B ^j   Graves, M ^k   Ross, M ^l   Sorenson, E J ^m   Kelkar, P ^p   Parry, G ⁿ   Olney, R ^o   more..

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^j MAYO CLINIC   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF KENTUCKY   (United States)

^m MAYO CLINIC   (United States)

ⁿ UNIVERSITY OF MINNESOTA   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; PLACEBO;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARM MUSCLE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOOT; HUMAN; ISOMETRIC EXERCISE; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME; VITAL CAPACITY; WALKING;

EID: 0035836649     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.56.7.843     Document Type: Article

References (17)

1. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis
2. Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: Report of the Quality Standards Subcommittee of the American Academy of Neurology
3. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis
4. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis
5. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on research
6. The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group
7. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis
8. Functional significance of upper and lower motor neuron impairment in amyotrophic lateral sclerosis
9. Quantitative motor assessment in amyotrophic lateral sclerosis
10. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis
11. Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with amyotrophic lateral sclerosis
12. Controlled trial of nimodipine in amyotrophic lateral sclerosis
13. A clinical trial of verapamil in amyotrophic lateral sclerosis
14. Treatment of ALS with high dose pulse cyclophosphamide